Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data

Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting